These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A novel mHealth application for improving HIV and Hepatitis C knowledge in individuals with opioid use disorder: A pilot study. Ochalek TA; Heil SH; Higgins ST; Badger GJ; Sigmon SC Drug Alcohol Depend; 2018 Sep; 190():224-228. PubMed ID: 30056321 [TBL] [Abstract][Full Text] [Related]
10. Supervised dosing with a long-acting opioid medication in the management of opioid dependence. Saulle R; Vecchi S; Gowing L Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011983. PubMed ID: 28447766 [TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Marsch LA; Moore SK; Borodovsky JT; Solhkhah R; Badger GJ; Semino S; Jarrett K; Condon KD; Rossettie K; Vincent P; Hajizadeh N; Ducat E Addiction; 2016 Aug; 111(8):1406-15. PubMed ID: 26918564 [TBL] [Abstract][Full Text] [Related]
12. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial. Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256 [TBL] [Abstract][Full Text] [Related]
14. Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail. Lee JD; Malone M; McDonald R; Cheng A; Vasudevan K; Tofighi B; Garment A; Porter B; Goldfeld KS; Matteo M; Mangat J; Katyal M; Giftos J; MacDonald R JAMA Netw Open; 2021 Sep; 4(9):e2123032. PubMed ID: 34495340 [TBL] [Abstract][Full Text] [Related]
15. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial. Dunn KE; Tompkins DA; Bigelow GE; Strain EC JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791 [TBL] [Abstract][Full Text] [Related]
17. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder. Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869 [TBL] [Abstract][Full Text] [Related]
18. Flexible Buprenorphine/Naloxone Model of Care for Reducing Opioid Use in Individuals With Prescription-Type Opioid Use Disorder: An Open-Label, Pragmatic, Noninferiority Randomized Controlled Trial. Jutras-Aswad D; Le Foll B; Ahamad K; Lim R; Bruneau J; Fischer B; Rehm J; Wild TC; Wood E; Brissette S; Gagnon L; Fikowski J; Ledjiar O; Masse B; Socias ME; Am J Psychiatry; 2022 Oct; 179(10):726-739. PubMed ID: 35702828 [TBL] [Abstract][Full Text] [Related]
19. Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder: A Randomized Clinical Trial. Walsh SL; Comer SD; Lofwall MR; Vince B; Levy-Cooperman N; Kelsh D; Coe MA; Jones JD; Nuzzo PA; Tiberg F; Sheldon B; Kim S JAMA Psychiatry; 2017 Sep; 74(9):894-902. PubMed ID: 28655025 [TBL] [Abstract][Full Text] [Related]
20. Bupropion Slow Release vs Placebo With Adaptive Incentives for Cocaine Use Disorder in Persons Receiving Methadone for Opioid Use Disorder: A Randomized Clinical Trial. Ware OD; Sweeney MM; Cunningham C; Umbricht A; Stitzer M; Dunn KE JAMA Netw Open; 2023 Mar; 6(3):e232278. PubMed ID: 36920397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]